Myeloma and Related Diseases Registry

Helping clinicians and hospitals to provide the best possible care to people with multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia or plasmacytoma.

Find out more

This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.

What is the registry?

Learn about how the registry works and the data we collect.
Benefits

Participation in the registry provides advantages for sites and patients.
About our projects

Find out about MRDR projects and how registry data is being used.
3410

Patients accrued

2311

Patients with multiple myeloma

43

Number of approved sites

411

Biobank participants

Latest news

First patient for FRAIL-M trial
26 Nov 2019

FRAIL-M, a trial using MRDR infrastructure, has commenced recruitment.

Read more
MRDR’s, Dr Jessie Zhao, awarded Snowdome grant at Blood 2019
25 Oct 2019

Dr Jessie Zhao's presentation on treatment patterns in myeloma was awarded a Snowdome travel grant.

Read more
MRDR at Blood 2019 conference
23 Oct 2019

The MRDR was well represented at the Blood 2019 conference in Perth in October.

Read more
MRDR at the International Myeloma Workshop
16 Sep 2019

The MRDR had a busy and productive meeting at the IMW in Boston, USA.

Read more

Participating organisations